表纸
市场调查报告书

第一型糖尿病:市场竞争环境 (到2026年)

Type 1 Diabetes: Competitive Landscape to 2026

出版商 GlobalData 商品编码 731757
出版日期 内容资讯 英文 48 Pages
订单完成后即时交付
价格
第一型糖尿病:市场竞争环境 (到2026年) Type 1 Diabetes: Competitive Landscape to 2026
出版日期: 2018年09月30日内容资讯: 英文 48 Pages
简介

本报告提供第一型糖尿病 (T1D)的治疗药临床实验、上市预测相关分析,临床实验的整体发展情形 (各地区的明细,初期/后期阶段的产品,主要的赞助商等) ,及主要开发中产品临床实验趋势 (各临床实验阶段),今后的市场规模的预测值,现在/未来的代表性企业的概要,今后的市场趋势预测等调查。

第1章 序论

第2章 摘要整理

第3章 简介

  • 分析范围
  • 疾病的概要与流行病学

第4章 开发中产品的评估

  • 开发中产品的概要
  • 开发中产品:各国/各地区的明细
  • 开发中产品:各分子类型/各标的的明细
  • 指定药临床实验趋势
  • 临床实验中的产品

第5章 临床实验的评估

  • 临床实验概要
  • 临床实验:第一型糖尿病临床实验的大赞助商
  • 临床实验:各地区的明细
  • 各治疗领域的进展预测
  • 参加率分析

第6章 在商业方面的评估

  • 主要的已上市产品
  • 现在/未来的企业

第7章 竞争环境分析 (总计11年份)

  • 活动的分类:概要
  • 美国
  • (5EU)欧洲主要5个国家
  • 日本、中国

第8章 附录

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: GDHC015CL

Type 1 Diabetes (T1D) is an autoimmune disease that permanently destroys beta cells of the pancreatic islet, which means that the body can no longer produce insulin. Type 1 Diabetes (T1D) can develop at any age, but is frequently observed in children and adolescents.Type 1 Diabetes (T1D) is the seventh most investigated indication within metabolic diseases by number of clinical trials, accounting for 8% of all clinical trials initiated since 1995.

Globally, Type 1 Diabetes (T1D) pipeline features 236 products across all stages of clinical development, with insulin and small molecules prominently featured in Phase III. Insulins, vaccines, and monoclonal antibodies dominate the early-stage pipeline.

Multiple big pharma developers (Novo Nordisk, Eli Lilly, and Sanofi) are investigating "smart insulin," insulin that can detect and respond to glucose levels. And for Stem Cell Therapy research, big pharma once again has a large presence, with AstraZeneca, Johnson and Johnson, Novo Nordisk, and Sanofi gearing up to develop novel treatments that target diabetes.

Overall, it is expected that new insulins and SGLT inhibitor approvals will drive Type 1 Diabetes market growth during the next decade.

The report "Type 1 Diabetes: Competitive Landscape to 2026", provides an assessment of the pipeline, clinical, and commercial landscape of Type 1 Diabetes along with an analysis of key market events and the future competitive environment.

Scope

This report combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace. Components of the slide deck include -

  • Pipeline Assessment: regional breakdown, promising late-stage products, early-stage pipeline by molecule type
  • Clinical Trials Assessment: trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics
  • Commercial Assessment: leading marketed products, current and future players
  • Competitive Landscape Analysis: key market events (2016-2026).

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global Type 1 Diabetes (T1D) market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Type 1 Diabetes (T1D) market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1. Preface 2

  • 1.1 Table of Contents 2
  • 1.2 Abbreviations 3
  • 1.3 Related Reports 4
  • 1.4 Upcoming Related Reports 5

2. Executive Summary 6

  • 2.2 Key Findings 7
  • 2.2 Key Events 8

3. Introduction 9

  • 3.1 Report Scope 10
  • 3.2 Disease Overview and Epidemiology 12

4. Pipeline Assessment 14

  • 4.1 Pipeline Overview 15
  • 4.2 Pipeline Breakdown by Region/Country 17
  • 4.3 Pipeline Breakdown by Molecule Type and Target 18
  • 4.4 Drug Review Designations 19
  • 4.5 Products in Clinical Development 20

5. Clinical Trial Assessment 22

  • 5.1 Clinical Trials Overview 23
  • 5.2 Top Sponsors of Clinical Trials in T1D 24
  • 5.3 Trial Breakdown by Region 26
  • 5.4 Therapy Area Perspective 27
  • 5.5 Enrollment Analytics 28

6 Commercial Assessment 31

  • 6.1 LeadingMarketed Products 32
  • 6.2 Current & Future Players 33

7. Competitive Landscape Analysis (2016-2026) 34

  • 7.1 Events Classification Overview 35
  • 7.2 US 36
  • 7.3 5EU 37
  • 7.4 Japan and China 38

8 Appendix 39

  • 8.1 Sources 40
  • 8.2 Methodology 41
  • 8.3 Key Events Included in the Analysis 42
  • 8.4 About the Authors 43
  • 8.5 About GlobalData 46
  • 8.6 Disclaimer 48